title: The spinal antinociceptive effects of cholinergic drugs in rats: receptor subtype specificity in different nociceptive tests.
abstract: BACKGROUND
  Several studies have shown that muscarinic cholinergic agonists cause antinociception in humans and animals when given by both spinal and non-spinal parenteral routes. It is uncertain which subtype of muscarinic receptor is involved in spinally mediated antinociceptive effects caused by these drugs. The cholinergic receptor agonists McN-A-343 (M1 selective; 3.89 to 389 nmol) and carbachol (non-selective; 0.029 to 29 nmol) were used in a rat acute pain model to investigate the involvement of M1 and non-M1 subtypes in spinally mediated antinociception. The drugs were injected intrathecally and results from experiments in which drug actions were carefully confined to the spinal cord were used to construct agonist dose response curves.
  
  
  RESULTS
  McN-A-343 frequently diffused rostrally to the brain, away from the lumbosacral site of injection. Thus, in spite of its receptor subtype selectivity, McN-A-343 is a poor probe to use in attempting to identify receptor subtypes involved in spinal cord antinociceptive systems. However, in some experiments McN-A-343 caused spinally mediated antinociception assessed by the electrical current threshold test. Antinociception assessed by the tail flick latency test with intrathecal McN-A-343 was observed and found to involve supraspinal mechanisms. Carbachol caused spinally mediated antinociception assessed by both electrical current threshold and tail flick latency.
  
  
  CONCLUSIONS
  The results suggest that M1 receptors are involved in spinally mediated antinociception revealed by electrical current threshold; other cholinergic receptors (non-M1) are involved in thermal antinociception at the spinal cord. This contrasts with previous work on spinally mediated cholinergic antinociception. These differences are believed to be due to difficulties in restricting the action of these drugs to the spinal cord.
authors.affiliation: Department of Anaesthesia, Monash University, Clayton, Victoria, 3168, Australia. m.lograsso@med.monash.edu.au
authors.forename: Michael
authors.initials: M
authors.lastname: Lograsso
authors.forename: Ray
authors.initials: R
authors.lastname: Nadeson
authors.forename: Colin S
authors.initials: CS
authors.lastname: Goodchild
mesh_terms: D008455:(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002217:Carbachol / Q000627:therapeutic use; D018678:Cholinergic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D008297:Male; D018721:Muscarinic Agonists / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D043643:Receptor, Muscarinic M1 / Q000378:metabolism; D013116:Spinal Cord / Q000187:drug effects*
chemical_list: D018678:Cholinergic Agents; D018721:Muscarinic Agonists; D043643:Receptor, Muscarinic M1; D008455:(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride; D002217:Carbachol